Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Mar;67(3):441–446. doi: 10.1038/bjc.1993.85

Pre-clinical evaluation of a novel chloroethylating agent, Clomesone.

A M Matthew 1, R M Phillips 1, P M Loadman 1, M C Bibby 1
PMCID: PMC1968247  PMID: 8382507

Abstract

The in vitro activity of the novel chloroethylating agent, Clomesone, was investigated in a panel of established murine and human tumour cell lines. In vivo anti-tumour activity was examined against three transplantable adenocarcinomas of the mouse colon and in vivo bone marrow toxicity was assessed using a spleen colony forming unit assay. The pharmacokinetic behaviour of the drug in vivo and drug stability in vitro was analysed by gas chromatography with electron capture detection. Clomesone exhibited no activity in vitro against the majority of cell lines derived from solid human colorectal carcinomas. Anti-tumour activity against the murine tumours in vivo was not impressive and was accompanied by myelosuppression. Pharmacokinetic data suggested that the lack of in vivo activity was due to the failure to achieve effective anti-neoplastic drug concentrations at the tumour site. It was concluded that this study found no evidence to suggest that Clomesone was toxicologically more selective than the chloroethylnitrosoureas.

Full text

PDF
441

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bibby M. C., Double J. A., Morris C. M. Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1361–1364. doi: 10.1016/0277-5379(88)90229-5. [DOI] [PubMed] [Google Scholar]
  2. Bibby M. C., Double J. A., Wahed I. A., Hirbawi N., Baker T. G. The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide. Br J Cancer. 1988 Aug;58(2):139–143. doi: 10.1038/bjc.1988.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chan K. K., Barrientos A. Analysis of clomesone in plasma by gas chromatography-electrolytic conductivity detection. J Chromatogr. 1988 Jul 15;428(2):331–339. doi: 10.1016/s0378-4347(00)83924-9. [DOI] [PubMed] [Google Scholar]
  4. Cheng C. J., Fujimura S., Grunberger D., Weinstein I. B. Interaction of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) with nucleic acids and proteins in vivo and in vitro. Cancer Res. 1972 Jan;32(1):22–27. [PubMed] [Google Scholar]
  5. Corbett T. H., Valeriote F. A., Baker L. H. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs. 1987;5(1):3–20. doi: 10.1007/BF00217664. [DOI] [PubMed] [Google Scholar]
  6. Double J. A., Ball C. R. Chemotherapy of transplanted adenocarcinomas of the colon in mice. Cancer Chemother Rep. 1975 Nov-Dec;59(6):1083–1089. [PubMed] [Google Scholar]
  7. Double J. A., Ball C. R., Cowen P. N. Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst. 1975 Jan;54(1):271–275. doi: 10.1093/jnci/54.1.271. [DOI] [PubMed] [Google Scholar]
  8. Double J. A., Bibby M. C. Therapeutic index: a vital component in selection of anticancer agents for clinical trial. J Natl Cancer Inst. 1989 Jul 5;81(13):988–994. doi: 10.1093/jnci/81.13.988. [DOI] [PubMed] [Google Scholar]
  9. Dykes D. J., Waud W. R., Harrison S. D., Jr, Laster W. R., Jr, Griswold D. P., Jr, Shealy Y. F., Montgomery J. A. Antitumor activity of 2-chloroethyl (methylsulfonyl)methanesulfonate (clomesone, NSC 33847) against selected tumor systems in mice. Cancer Res. 1989 Mar 1;49(5):1182–1186. [PubMed] [Google Scholar]
  10. Erickson L. C., Bradley M. O., Ducore J. M., Ewig R. A., Kohn K. W. DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas. Proc Natl Acad Sci U S A. 1980 Jan;77(1):467–471. doi: 10.1073/pnas.77.1.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gibson N. W., Erickson L. C., Kohn K. W. DNA damage and differential cytotoxicity produced in human cells by 2-chloroethyl (methylsulfonyl)methanesulfonate (NSC 338947), a new DNA-chloroethylating agent. Cancer Res. 1985 Apr;45(4):1674–1679. [PubMed] [Google Scholar]
  12. Gibson N. W., Hartley J. A., Strong J. M., Kohn K. W. 2-Chloroethyl (methylsulfonyl)methanesulfonate (NSC-338947), a more selective DNA alkylating agent than the chloroethylnitrosoureas. Cancer Res. 1986 Feb;46(2):553–557. [PubMed] [Google Scholar]
  13. Marsoni S., Hoth D., Simon R., Leyland-Jones B., De Rosa M., Wittes R. E. Clinical drug development: an analysis of phase II trials, 1970-1985. Cancer Treat Rep. 1987 Jan;71(1):71–80. [PubMed] [Google Scholar]
  14. McElhinney R. S., McCormick J. E., Bibby M. C., Double J. A., Atassi G., Dumont P., Pratesi G., Radacic M. Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice. Anticancer Drug Des. 1989 Jun;4(1):1–20. [PubMed] [Google Scholar]
  15. Pelfrene A., Mirvish S. S., Gold B. Induction of malignant bone tumors in rats by 1-(2-hydroxyethyl)-1-nitrosourea. J Natl Cancer Inst. 1976 Feb;56(2):445–446. doi: 10.1093/jnci/56.2.445. [DOI] [PubMed] [Google Scholar]
  16. Phillips R. M., Bibby M. C., Double J. A. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst. 1990 Sep 19;82(18):1457–1468. doi: 10.1093/jnci/82.18.1457. [DOI] [PubMed] [Google Scholar]
  17. Phillips R. M., Hulbert P. B., Bibby M. C., Sleigh N. R., Double J. A. In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer. 1992 Mar;65(3):359–364. doi: 10.1038/bjc.1992.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sariban E., Erickson L. C., Kohn K. W. Effects of carbamoylation on cell survival and DNA repair in normal human embryo cells (IMR-90) treated with various 1-(2-chloroethyl)-1-nitrosoureas. Cancer Res. 1984 Apr;44(4):1352–1357. [PubMed] [Google Scholar]
  19. Schofield R. Assessment of cytotoxic injury to bone marrow. Br J Cancer Suppl. 1986;7:115–125. [PMC free article] [PubMed] [Google Scholar]
  20. Shealy Y. F., Krauth C. A., Laster W. R., Jr 2-Chloroethyl (methylsulfonyl)methanesulfonate and related (methylsulfonyl)methanesulfonates. Antineoplastic activity in vivo. J Med Chem. 1984 May;27(5):664–670. doi: 10.1021/jm00371a019. [DOI] [PubMed] [Google Scholar]
  21. Shealy Y. F., Krauth C. A., Struck R. F., Montgomery J. A. 2-haloethylating agents for cancer chemotherapy. 2-haloethyl sulfonates. J Med Chem. 1983 Aug;26(8):1168–1173. doi: 10.1021/jm00362a016. [DOI] [PubMed] [Google Scholar]
  22. Swenson D. H., Frei J. V., Lawley P. D. Synthesis of 1-(2-hydroxyethyl)-1-nitrosourea and comparison of its carcinogenicity with that of 1-ethyl-1-nitrosourea. J Natl Cancer Inst. 1979 Dec;63(6):1469–1473. [PubMed] [Google Scholar]
  23. TILL J. E., McCULLOCH E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961 Feb;14:213–222. [PubMed] [Google Scholar]
  24. Tong W. P., Kohn K. W., Ludlum D. B. Modifications of DNA by different haloethylnitrosoureas. Cancer Res. 1982 Nov;42(11):4460–4464. [PubMed] [Google Scholar]
  25. Twentyman P. R., Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987 Sep;56(3):279–285. doi: 10.1038/bjc.1987.190. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES